EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

B-Cells and Plasmablasts as Architects of Autoimmune Disease: From Molecular Footprints to Precision Therapeutics

Julie Sarrand iD, Muhammad Soyfoo iD

Cells · 09.01.2026 · 15 (2) · 119

DOI: 10.3390/cells15020119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 09.01.2026. Verfasst von Julie Sarrand und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium. Hauptthemen laut MEDLINE: Autoimmune Diseases, B-Lymphocytes, Plasma Cells, Precision Medicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cells and plasmablasts have emerged as central organizers of autoimmune pathogenesis, extending far beyond their classical role as antibody-producing cells to orchestrate immune circuits, tissue microenvironments, and therapeutic trajectories. Advances in single-cell technologies, high-dimensional cytometry, and B-cell receptor sequencing have uncovered a dynamic continuum of B-cell differentiation programs that drive clinical heterogeneity across systemic autoimmune diseases. Plasmablasts, in particular, have gained recognition as highly responsive sensors of immune activation: they expand during flares, encode interferon-driven and extrafollicular responses, and correlate with disease severity. Autoantibody profiles, long viewed as static diagnostic signatures, are now understood as durable molecular footprints of distinct B-cell pathways. In this review, we propose an endotype-based framework integrating B-cell circuits with clinical phenotypes, illustrate therapeutic decision-making through mechanistic case vignettes, and outline future strategies combining immunomonitoring, multi-omics, and precision therapeutics. We further address translational challenges and discuss complementary approaches, including T-cell modulation, FcRn inhibition, and antigen-specific tolerization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesB-LymphocytesPlasma CellsPrecision MedicineHumansAnimals

Stichwörter der Autor:innen

B cellsB-cell endotypesCAR-T therapyautoantibodiesautoimmune diseaseextrafollicular pathwaygerminal centerimmunomonitoringplasmablastsprecision medicine

Autor:innen und Institutionen

  • Department of Rheumatology, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

ORCID-Profile: Julie Sarrand, Muhammad Soyfoo

Zitieren

APA

Sarrand, J., & Soyfoo, M. (2026). B-Cells and Plasmablasts as Architects of Autoimmune Disease: From Molecular Footprints to Precision Therapeutics. Cells, 15(2), 119. https://doi.org/10.3390/cells15020119

Vancouver

Sarrand J, Soyfoo M. B-Cells and Plasmablasts as Architects of Autoimmune Disease: From Molecular Footprints to Precision Therapeutics. Cells. 2026;15(2):119. doi:10.3390/cells15020119

BibTeX
@article{Sarrand2026,
  author = {Sarrand, Julie and Soyfoo, Muhammad},
  title = {B-Cells and Plasmablasts as Architects of Autoimmune Disease: From Molecular Footprints to Precision Therapeutics},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {119},
  doi = {10.3390/cells15020119}
}
Kostenlos starten →